利奈唑胺是否需要血药浓度监测?  

Whether therapeutic drug monitoring is necessary for linezolid?

作　　者：曹伟[1] 卢志品[1] 余剑华[2] 

机构地区：[1]厦门大学附属第一医院药学部,福建厦门361003 [2]厦门大学附属第一医院重症医学科,福建厦门361003

出　　处：《中国新药与临床杂志》2016年第10期690-694,共5页Chinese Journal of New Drugs and Clinical Remedies

摘　　要：利奈唑胺非肝药酶代谢,约35%以原型经肾排泄,说明书提示其浓度受其他药物影响轻微,肾功能不全患者无需调整剂量,但临床研究表明肾功能不全患者利奈唑胺所致血小板减少症或贫血发生率增高与利奈唑胺高暴露相关,且利奈唑胺与某些药物存在的相互作用可显著影响其血药浓度、利奈唑胺的血药浓度在危重症患者中个体差异大,应进行血药浓度监测。Linezolid is not metabolized by CYP450s and only approximately 35% of the prototype was excreted via the kidney, and its label suggests that its concentration is affected by other drugs slightly and no dose adjustment is recommended to patients with renal impairment. Nevertheless, clinic studies showed that the development of linezolid- induced thrombocytopenia and anemia was related to the high linezolid exposure in patients with impaired renal function, and the interaction between linezolid and other drugs may significantly affect its concentration. Considering these factors and the significant variability of linezolid concentration in critically ill patients, the therapeutic drug monitoring is necessary for linezolid to ensure its efficiency and safety.

关 键 词：利奈唑胺 肾功能不全 血小板减少 药物相互作用 药物监测 

分 类 号：R969.1[医药卫生—药理学]